重症监护病房中的癫痫持续状态
本文综述重症监护病房(ICU)中癫痫持续状态的诊治。惊厥性癫痫持续状态可无需脑电图诊断,非惊厥性则必须脑电图。初始治疗为快速给予苯二氮䓬类,随后选用(磷)苯妥英、左乙拉西坦或丙戊酸之一;其他药物如拉考沙胺或布瓦西坦应用增多。难治性癫痫持续状态常用咪达唑仑或丙泊酚持续输注,超难治性可考虑氯胺酮和巴比妥类。难治性和超难治性几乎均为非惊厥性,需连续视频脑电监测。短期死亡率10%–15%,难治性25%,超难治性近40%。
要点
- 惊厥性癫痫持续状态可无需脑电图诊断,非惊厥性癫痫持续状态必须依靠脑电图可靠诊断。
- 初始治疗:快速给予苯二氮䓬类,随后选用(磷)苯妥英、左乙拉西坦或丙戊酸之一静脉给药。
- 难治性癫痫持续状态最常用咪达唑仑或丙泊酚持续输注,替代方案包括进一步非镇静抗癫痫药和非药物方法。
- 难治性和超难治性癫痫持续状态几乎均为非惊厥性,需连续视频脑电监测指导管理。
- 短期死亡率: responsive 10%、难治性25%、超难治性近40%,主要与年龄增长、病因和合并症相关。
适用人群与场景
- ICU中管理的癫痫持续状态患者,包括最严重病例。
诊断标准与关键阈值
- 惊厥性癫痫持续状态可无需脑电图诊断。
- 非惊厥性癫痫持续状态需脑电图可靠诊断。
- 经苯二氮䓬类和非镇静静脉抗癫痫药治疗后仍持续的癫痫持续状态称为难治性。
- 停用丙泊酚或咪达唑仑后复发或继续持续的癫痫持续状态称为超难治性。
处置流程与药物剂量
- 初始治疗:快速给予苯二氮䓬类,随后给予以下非镇静静脉抗癫痫药之一:(磷)苯妥英、左乙拉西坦或丙戊酸。
- 其他非镇静抗癫痫药应用增多,如拉考沙胺或布瓦西坦。
- 难治性癫痫持续状态:最常用咪达唑仑或丙泊酚持续输注。
- 难治性癫痫持续状态的替代方案:进一步非镇静抗癫痫药和非药物方法。
- 超难治性癫痫持续状态:可包括非镇静或镇静药物,如氯胺酮和巴比妥类。
- 难治性和超难治性癫痫持续状态需连续视频脑电监测。
- 尽可能管理癫痫的潜在病因,尤其对自身免疫性脑炎患者至关重要。
红旗征与不能漏的情况
- 难治性和超难治性癫痫持续状态几乎均为非惊厥性,需连续视频脑电监测。
- 自身免疫性脑炎患者需特别关注病因管理。
研究设计与关键结果
- 综述指出癫痫持续状态是常见医疗急症,与显著发病率和死亡率相关。
- 遵循已发表指南的管理最有可能改善结局。
- 短期死亡率范围为10%至15%,主要与年龄增长、潜在病因和内科合并症相关。
- 死亡率随治疗难治性上升: responsive 病例10%,难治性25%,超难治性近40%。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 惊厥性癫痫持续状态可依据临床诊断启动治疗,非惊厥性需脑电图确诊。
- 初始治疗应快速给予苯二氮䓬类,随后选用(磷)苯妥英、左乙拉西坦或丙戊酸之一。
- 难治性癫痫持续状态采用咪达唑仑或丙泊酚持续输注,并连接连续视频脑电监测。
- 超难治性癫痫持续状态可考虑氯胺酮和巴比妥类。
- 应积极查找并处理潜在病因,尤其自身免疫性脑炎。
指南或共识出处
- Intensive Care Med 发表的综述《Status epilepticus in the ICU》。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Status epilepticus (SE) is a common medical emergency associated with significant morbidity and mortality. Management that follows published guidelines is best suited to improve outcomes, with the most severe cases frequently being managed in the intensive care unit (ICU). Diagnosis of convulsive SE can be made without electroencephalography (EEG), but EEG is required to reliably diagnose nonconvulsive SE. Rapidly narrowing down underlying causes for SE is crucial, as this may guide additional management steps. Causes may range from underlying epilepsy to acute brain injuries such as trauma, cardiac arrest, stroke, and infections. Initial management consists of rapid administration of benzodiazepines and one of the following non-sedating intravenous antiseizure medications (ASM): (fos-)phenytoin, levetiracetam, or valproate; other ASM are increasingly used, such as lacosamide or brivaracetam. SE that continues despite these medications is called refractory, and most commonly treated with continuous infusions of midazolam or propofol. Alternatives include further non-sedating ASM and non-pharmacologic approaches. SE that reemerges after weaning or continues despite management with propofol or midazolam is labeled super-refractory SE. At this step, management may include non-sedating or sedating compounds including ketamine and barbiturates. Continuous video EEG is necessary for the management of refractory and super-refractory SE, as these are almost always nonconvulsive. If possible, management of the underlying cause of seizures is crucial particularly for patients with autoimmune encephalitis. Short-term mortality ranges from 10 to 15% after SE and is primarily related to increasing age, underlying etiology, and medical comorbidities. Refractoriness of treatment is clearly related to outcome with mortality rising from 10% in responsive cases, to 25% in refractory, and nearly 40% in super-refractory SE.
参考来源
- Rossetti AO, Claassen J, Gaspard N, et al. Status epilepticus in the ICU. Intensive Care Med. 2023. PMID: 38117319. doi:10.1007/s00134-023-07263-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。